The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...

Results from a phase 1/2 clinical trial (NCT05099172) show the safety and efficacy of sevabertinib (BAY2927088) in patients ...

Vorasidenib significantly improved median progression-free survival and time to next intervention in IDH-mutant grade 2 ...

Community-based CAR T-cell therapy improves access, reducing travel burdens and hospital admissions for patients with blood ...

A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.

Whole-genome sequencing (WGS) of tumor and germline can generate actionable molecular insights that can guide precision medicine efforts in salivary gland cancer (SGC), according to a new study in JCO ...

In the study, investigators examined temporal changes in the number of cancer clinical trials and analyzed correlations to ...

During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on ...

MUD HCT is associated with better survival outcomes and fewer severe complications compared to haploidentical HCT in acute ...

October 2025 proved to be a significant month for the oncology landscape, marked by a wave of key regulatory decisions from ...

Combination therapy with cadonilimab, a first-in-class bispecific antibody targeting both PD-1 and CTLA-4, and chemotherapy offers encouraging antitumor activity and manageable safety as a first-line ...

Reclassified disease response criteria at 28 days of treatment for acute graft-vs-host disease (GVHD) improved prediction of 6-month nonrelapse mortality (NRM) compared with conventional criteria in ...